FDA Defines Ground Rules For Evolving DES Clinical Trial Paradigm
This article was originally published in The Gray Sheet
Executive Summary
Foreign drug-eluting stent trial strategies should be discussed with FDA at pre-IDE meetings to ensure that data outside the U.S. will be acceptable for premarket submissions, CDRH Division of Cardiovascular Devices Director Bram Zuckerman recommends
You may also be interested in...
JAMA Articles Suggest Non-Inferiority Trials Are, In Fact, Sometimes Inferior
Non-inferiority and equivalence trials are often poorly conducted and poorly reported, according to a series of articles in the Journal of the American Medical Association that could have particular implications for device firms
JAMA Articles Suggest Non-Inferiority Trials Are, In Fact, Sometimes Inferior
Non-inferiority and equivalence trials are often poorly conducted and poorly reported, according to a series of articles in the Journal of the American Medical Association that could have particular implications for device firms
Preclinical, Clinical Drug-Eluting Stent Trial Insights Provided By FDAers
Drug-eluting stent manufacturers should adopt robust test methods for replicating failure rates observed in animal models, according to CDRH Division of Cardiovascular Devices Biomedical Engineer Jonette Foy